Eikon Therapeutics Presents Updated EIK1001 Data from TeLuRide-005 at the European Society for Medical Oncology Congress

Eikon Therapeutics presented updated data for EIK1001, a TLR7/8 dual-agonist, combined with pembrolizumab and chemotherapy for first-line stage 4 NSCLC at ESMO Congress. The squamous cohort showed 72% ORR and 100% DCR with 12.9-month median duration of response. The combination was well-tolerated with an adverse event profile similar to standard-of-care alone, supporting outpatient administration. The Phase 2/3 TeLuRide-008 trial is actively enrolling with interim analysis expected in 2H 2027.